Is neuroendocrine cell differentiation detected using chromogranin a from patients with bone metastatic prostate cancer a prognostic factor for outcome?

Oncology Reports

Volumn 15, Issue 5, 2006, Pages 1309-1313

  Yamada, Yoshiaki ^a   Nakamura, Kogenta ^a   Aoki, Shigeyuki ^a   Taki, Tomohiro ^a   Matsubara, Hiroyuki ^a   Sai, Shotoku ^a   Naruse, Katsuya ^a   Tobiume, Motoi ^a   Katsuda, Remi ^a   Zennami, Kenji ^a   Honda, Nobuaki ^a   Nakagawa, Atsuko ^a   Ikeda, Hiroshi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone metastatic prostate cancer; Chromogranin A; Immunohistochemistry; Neuroendocrine differentiation; Outcome

Indexed keywords

ANTIANDROGEN; CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN A, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BONE TUMOR; CANCER STAGING; CELL DIFFERENTIATION; DISEASE FREE SURVIVAL; ENZYME IMMUNOASSAY; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE NEOPLASMS; CELL DIFFERENTIATION; CHROMOGRANIN A; CHROMOGRANINS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33745007118     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.5.1309     Document Type: Article

References (21)

1. Abrahamsson PA: Neuroendocrine differentiation in prostate carcinoma. Prostate 39: 135-148, 1999.
2. Bonkhoff H: Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate 8 (Suppl.): 18-22, 1998.
3. Tanaka M, Suzuki Y, Takaoka K, et al: Progression of prostate cancer to neuroendocrine cell tumor. Int J Urol 8: 431-437, 2001.
4. Di Sant'Agnese PA: Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 70 (Suppl.): 254-268, 1992.
5. Di Sant'Agnese PA and Cockett AT: The prostatic endocrineparacrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol 152: 1927-1931, 1994. (Pubitemid 24322661)
6. Ather MH and Abbas F: Prognostic significance of neuroendocrine differentiation in prostate cancer. Eur Urol 38: 535-542, 2000.
7. McWilliam LJ, Manson C and George NJ: Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 80: 287-290, 1997. (Pubitemid 28318898)
8. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG and van der Kwast TH: The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 158: 171-174, 1997. (Pubitemid 27251617)
9. Ischia R, Hobisch A, Bauer R, et al: Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. J Urol 163: 1161-1165, 2000. (Pubitemid 30169383)
10. Berruti A, Dogliotti L, Mosca A, et al: Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 88: 2590-2597, 2000. (Pubitemid 30331968)
11. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N and Ito H: Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 167: 512-515, 2002. (Pubitemid 34074517)
12. Gleason DF: Histological grading of prostate cancer. A perspective. Hum Pathol 23: 273-279, 1992.
13. Sobin LH and Wittekind CH: TNM Classification of Malignant Tumors. 5th edition. Wiley-Liss Inc., 1997.
14. Debes JD and Tindall DJ: Mechanisms of androgen-refractory prostate cancer. N Eng J Med 351: 1488-1490, 2004. (Pubitemid 39315314)
15. Casella R, Bubendorf L, Sauter G, Moch H, Mihatsch MJ and Gasser TC: Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol 160: 406-410, 1998. (Pubitemid 29476688)
16. Bostwick DG, Qian J, Pacelli A, et al: Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 168: 1204-1211, 2002.
17. Pruneri G, Galli S, Rossi RS, et al: Chromogranin A and B and Secretogranin in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate 34: 113-120, 1998. (Pubitemid 28080038)
18. Noordzji MA, van der Kwast TH, van Steenbrugge GJ, Hop WJ and Schroder FH: The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 62: 252-258, 1995.
19. Aprikian AG, Cordon-Cardo C, Fair WR, et al: Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 151: 914-919, 1994. (Pubitemid 24083459)
20. Jongsma J, Oomen MH, Noordzij MA, et al: Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 60: 741-748, 2000. (Pubitemid 30094576)
21. Nagakawa O, Fujiuchi Y, Fuse H and Saiki I: Differential effect of chromogranin A fragments on invasion and growth of prostate cancer cells in vitro. Urology 62: 553-558, 2003. (Pubitemid 36999896)